Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

BACKGROUND Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine-cisplatin chemotherapy in patients with advanced gastric or gastro-oesophageal junction cancer. METHODS In our open-label, randomised phase 3 trial (EXPAND), we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction. We enrolled patients at 164 sites (teaching hospitals and clinics) in 25 countries, and randomly assigned eligible participants (1:1) to receive first-line chemotherapy with or without cetuximab. Randomisation was done with a permuted block randomisation procedure (variable block size), stratified by disease stage (M0 vs M1), previous oesophagectomy or gastrectomy (yes vs no), and previous (neo)adjuvant (radio)chemotherapy (yes vs no). Treatment consisted of 3-week cycles of twice-daily capecitabine 1000 mg/m(2) (on days 1-14) and intravenous cisplatin 80 mg/m(2) (on day 1), with or without weekly cetuximab (400 mg/m(2) initial infusion on day 1 followed by 250 mg/m(2) per week thereafter). The primary endpoint was progression-free survival (PFS), assessed by a masked independent review committee in the intention-to-treat population. We assessed safety in all patients who received at least one dose of study drug. This study is registered at EudraCT, number 2007-004219-75. FINDINGS Between June 30, 2008, and Dec 15, 2010, we enrolled 904 patients. Median PFS for 455 patients allocated capecitabine-cisplatin plus cetuximab was 4.4 months (95% CI 4.2-5.5) compared with 5.6 months (5.1-5.7) for 449 patients who were allocated to receive capecitabine-cisplatin alone (hazard ratio 1.09, 95% CI 0.92-1.29; p=0.32). 369 (83%) of 446 patients in the chemotherapy plus cetuximab group and 337 (77%) of 436 patients in the chemotherapy group had grade 3-4 adverse events, including grade 3-4 diarrhoea, hypokalaemia, hypomagnesaemia, rash, and hand-foot syndrome. Grade 3-4 neutropenia was more common in controls than in patients who received cetuximab. Incidence of grade 3-4 skin reactions and acne-like rash was substantially higher in the cetuximab-containing regimen than in the control regimen. 239 (54%) of 446 in the cetuximab group and 194 (44%) of 436 in the control group had any grade of serious adverse event. INTERPRETATION Addition of cetuximab to capecitabine-cisplatin provided no additional benefit to chemotherapy alone in the first-line treatment of advanced gastric cancer in our trial. FUNDING Merck KGaA.

[1]  R. Langer,et al.  Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) , 2011, BMC Cancer.

[2]  S. Kubicka,et al.  Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  H. Grabsch,et al.  HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[4]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[5]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[7]  Tae Won Kim,et al.  A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer , 2011, Investigational New Drugs.

[8]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[12]  C. Bokemeyer,et al.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Heinemann,et al.  Cetuximab in the treatment of metastatic colorectal cancer , 2007, Expert opinion on biological therapy.

[14]  M. J. van de Vijver,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[15]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[16]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Y. Jeon,et al.  EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number , 2008, Histopathology.

[18]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[19]  J. Ajani,et al.  Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .

[20]  A. Norman,et al.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.

[22]  Y. Bang,et al.  Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer , 2009, British Journal of Cancer.

[23]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[24]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Norman,et al.  Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Bardelli,et al.  Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) , 2009, British Journal of Cancer.

[27]  N. Pavlakis,et al.  Management of advanced gastric cancer , 2012, Expert review of gastroenterology & hepatology.

[28]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  D. Cunningham,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Ku,et al.  Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters , 2012, Cancer Chemotherapy and Pharmacology.

[32]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[35]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  F. Lordick,et al.  Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) , 2010, British Journal of Cancer.

[37]  M. Bonetti,et al.  A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. , 2000, Statistics in medicine.

[38]  H. Sorbye,et al.  Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[40]  K. O'Byrne,et al.  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. , 2012, The Lancet. Oncology.

[41]  M. Ebert,et al.  A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  E. Chiorean Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011 .